MARKET
IPO

PLTX

Peloton
PLTX
NASDAQ
Upcoming IPOs
Expected Listing Date: - -
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-20.95~-18.49
-
4.04~4.58
666.92M~755.84M
Biotechnology & Medical Research
2019-07-10
Public Filing
View Prospectus
Pending
Offering
Price Range: 15.00~17.00
Shares to be Issued: 9375.00K
Pending
Offering End Date
Offering Price: Pending
Post IPO Outstanding: 44.46M
Listed
No Data
About PLTX
Peloton Therapeutics, Inc. is a clinical stage pharmaceutical company. The Company is focused on developing medicines for patients with cancer and other conditions. The Company’s product pipeline include Hypoxia-inducible factor-2α (HIF-2α). HIF-2α is a transcription factor that, in part, regulates the body’s response to diminished availability of oxygen. The Company’s lead drug candidate, PT2977, is an oral HIF-2α. The Company is focused on developing PT2977 for the treatment of kidney cancer, specifically metastatic clear cell renal cell carcinoma (mRCC) and von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC). HIF-2α is aberrantly activated in these diseases as a result of the inactivity of the VHL tumor suppressor. The Company is also developing PT2567, an oral HIF-2α inhibitor, for non-oncology indications.

Webull offers Peloton stock information, including NASDAQ: PLTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLTX stock methods without spending real money on the virtual paper trading platform.